A look at the financing, M&A and alliance activity in April-June 2018
• By Amanda Micklus and Maureen Riordan
Second quarter device financing totaled $3.4 billion, less than half of the Q1 aggregate. Conversely, the $10.6 billion in device M&As was a 58% upsurge over the previous quarter. Like the device trends, total Q2 diagnostics financings (at $959 million) showed a 36% decline from Q1, while the $4.8 billion in M&A volume exhibited a significant increase over the previous quarter.
Device companies brought in a total of $3.4 billion in financing during the second quarter, a significant decrease – less than half – compared with Q1’s aggregate $7.6 billion. Still, over $5 billion of the first quarter figure was outlier Siemens Healthineers AG’s IPO [See Deal], and excluding that deal means that Q2 activity actually performed better. Debt financing once again had a strong showing, in Q2, and follow-on public offerings also represented a substantial amount (see Exhibit 1).
Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.
